AP — For the second time, a study testing an experimental antibody drug for COVID-19 has been paused to investigate a possible safety issue in hospitalized patients.
Regeneron Pharmaceuticals Inc. said Friday that independent monitors had recommended placing on hold enrollment of the most severely ill patients — those who need intense oxygen treatment or breathing machines — because of a potential safety problem and an unfavorable balance of risks and benefits.
The study can continue to test the two-antibody drug combo in hospitalized patients who need little or no extra oxygen, the monitors said. Other studies in mild or moderately ill people also are continuing. US President Donald Trump got the Regeneron drug when he was sickened earlier this month.
Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. But it can take several weeks for the most effective ones to form. The experimental drugs aim to help immediately, by supplying concentrated versions of one or two antibodies that worked best against the coronavirus in lab and animal tests.
Earlier this month, a different group of monitors recommended pausing enrollment in a US National Institutes of Health study testing an Eli Lilly antibody drug to investigate a possible safety issue in hospitalized patients. On Monday, the NIH said no safety problem had been verified, but they stopped the study because the drug didn’t seem to work in that situation.
“These kinds of results are informing us about the timing of the benefit,” said Dr. Myron Cohen, a University of North Carolina virologist who advises the government on COVID-19 treatments.
US President Donald Trump arrives at Walter Reed National Military Medical Center, in Bethesda, Maryland, October 2, 2020, on the Marine One helicopter after he tested positive for COVID-19. (AP Photo/Jacquelyn Martin)
Tests in animals suggest that antibody drugs work best when given early in infection to lower the amount of the virus in a patient’s body, he said. Once someone is very sick, the drugs may not help, but it’s too soon to know if that’s the case, he added.
Doctors already know that timing can matter when it comes to COVID-19 treatments. Studies suggest that dexamethasone and other steroids can lower the risk of death when given to very sick patients to tamp down an over-active immune system, but they may be harmful for those who are only mildly ill.
Lilly and Regeneron have asked the Food and Drug Administration to allow emergency use of their experimental antibody drugs for mild and moderately ill patients who don’t need hospitalization.
Regeneron said it would share Friday’s advice from independent monitors with the FDA and leaders of a separate study in the United Kingdom testing its drug in hospitalized patients.
Health - Latest - Google News
October 31, 2020 at 12:45AM
https://ift.tt/3kPQQo0
Study testing COVID antibody drug used to treat Trump halted for some patients - The Times of Israel
Health - Latest - Google News
https://ift.tt/2zrj9Ud
Bagikan Berita Ini
0 Response to "Study testing COVID antibody drug used to treat Trump halted for some patients - The Times of Israel"
Post a Comment